Safety of teriflunomide in Chinese adult patients with relapsing multiple sclerosis: A phase IV, 24-week multicenter study

• Published in: 中华医学杂志英文版 Vol. 138; no. 4; pp. 452 - 458
• Main Authors: Quan Chao, Zhou Hongyu, Yang Huan, Jiao Zheng, Zhang Meini, Zhang Baorong, Tan Guojun, Bu Bitao, Jin Tao, Li Chunyang, Xue Qun, Dong Huiqing, Shi Fudong, Qin Xinyue, Zhang Xinghu, Gao Feng, Zhang Hua, Wang Jiawei, Hu Xueqiang, Chen Yueting, Liu Jue, Qiu Wei
• Format: Journal Article
• Language: Chinese
• Published: Department of Neurology, Huashan Hospital, Shanghai Medical College, Fudan University, National Centre for Neurological Disorders, Shanghai 201206, China%Department of Neurology, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, China%Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China%Department of Pharmacy, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, China%Department of Neurology, The First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030012, China%Department of Neurology, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, China%Department of Neurology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, China%Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China%Department of Neurology, The First Hospital of Jilin University, Changchun, Jilin 130021, China%Department of Neurology, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia 010050, China%Department of Neurology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, China%Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China%Department of Neurology, Tianjin Medical University General Hospital, Tianjin 300052, China%Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China%Center of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China%Department of Neurology, Peking University First Hospital, Beijing100034, China%Department of Neurology, Beijing Hospital, Beijing 100730, China%Department of Neurology, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730 China%Department of Neurology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510630, China%Medical Department, Sanofi Investment Co., Ltd., Shanghai 200040, China 2025
• Subjects: ABCG2 c.421C>A; Population pharmacokinetics; Multiple sclerosis; Teriflunomide; Non randomized; Safety
• ISSN: 0366-6999
• DOI: 10.1097/CM9.0000000000002990

Background::Disease-modifying therapies have been approved for the treatment of relapsing multiple sclerosis (RMS). The present study aims to examine the safety of teriflunomide in Chinese patients with RMS.Methods::This non-randomized, multi-center, 24-week, prospective study enrolled RMS patients with variant (c.421C>A) or wild type ABCG2 who received once-daily oral teriflunomide 14 mg. The primary endpoint was the relationship between ABCG2 polymorphisms and teriflunomide exposure over 24 weeks. Safety was assessed over the 24-week treatment with teriflunomide. Results::Eighty-two patients were assigned to variant ( n = 42) and wild type groups ( n = 40), respectively. Geometric mean and geometric standard deviation (SD) of pre-dose concentration (variant, 54.9 [38.0] μg/mL; wild type, 49.1 [32.0] μg/mL) and area under plasma concentration-time curve over a dosing interval (AUC tau) (variant, 1731.3 [769.0] μg·h/mL; wild type, 1564.5 [1053.0] μg·h/mL) values at steady state were approximately similar betw